5/26/2025
Research Authors
Overview
SCIENTIFIC SCORE
Possibly Effective
Based on 8 Researches
7.1
USERS' SCORE
Good
Based on 14 Reviews
8
Supplement Facts
Serving Size: 1 Veg Capsule
Amount Per Serving
%DV
5-HTP (5-hydroxytryptophan) (from Griffonia simplicifolia Extract) (Seed)
100 mg
*
Top Medical Research Studies
7
5-HTP shows potential sleep benefits
We explored the impact of 5-hydroxytryptophan (5-HTP) on REM sleep behavior disorder in patients with Parkinson's disease. In a small, randomized, double-blind trial with 18 participants, we compared daily doses of 5-HTP to a placebo over four weeks. The results suggested that 5-HTP can improve sleep quality and stability without increasing REM sleep disorder episodes. However, the overall benefits were marginal and further research with larger groups and longer durations is essential to confirm these findings.
7
We conducted a randomized, double-blind study to examine the effects of 5-Hydroxytryptophan (5-HTP) on motor complications caused by levodopa in 12 Parkinson's disease patients. Throughout the 16-week trial, involving a crossover design, we compared the effects of 5-HTP with a placebo.
While our results showed potential benefits in reducing levodopa-induced dyskinesias, they remain preliminary and warrant further investigation in larger studies. Overall, this suggests that 5-HTP might help alleviate some motor issues in Parkinson's patients, but more research is needed to confirm its effectiveness.
While our results showed potential benefits in reducing levodopa-induced dyskinesias, they remain preliminary and warrant further investigation in larger studies. Overall, this suggests that 5-HTP might help alleviate some motor issues in Parkinson's patients, but more research is needed to confirm its effectiveness.
8
We evaluated how 5-hydroxy-tryptophan (5-HTP) might help reduce L-DOPA-induced dyskinesia (LID) in a Parkinson’s disease rat model. Through controlled studies, we found that 5-HTP significantly cut down LID by about 50% without compromising L-DOPA's effectiveness at lower doses. However, using higher doses showed some reduction in L-DOPA's therapeutic effects. Despite these variations, 5-HTP proved beneficial and could be a promising treatment option for reducing dyskinesia in Parkinson's patients, highlighting the serotonin system's critical role in managing these symptoms.
Most Useful Reviews
9
Improved emotional health
8 people found this helpful
Following the intake of 5-HTP, symptoms of depression, apathy, and anxiety diminish; sleep becomes regular, and overall mood improves significantly. Notably, it alleviates symptoms of migraine and Parkinson's disease while enhancing concentration and overall productivity. A dosage of 50 to 300 mg per day is recommended.
9
Enhances serotonin regulation
5-HTP increases serotonin, crucial for mood regulation and addressing depression, anxiety, and sleep issues. Studies indicate it aids in reducing Parkinson's symptoms across multiple areas, making it an effective supplement for patients struggling with this condition.
9
Boosts mood and sleep
5-HTP enhances mood by raising serotonin levels, significantly reducing anxiety and alleviating symptoms associated with Parkinson's disease. It also positively affects sleep quality by promoting deeper, more restful sleep, which is crucial for overall emotional and physical health.
Medical Researches
SCIENTIFIC SCORE
Possibly Effective
Based on 8 Researches
7.1
- All Researches
8
We evaluated how 5-hydroxy-tryptophan (5-HTP) might help reduce L-DOPA-induced dyskinesia (LID) in a Parkinson’s disease rat model. Through controlled studies, we found that 5-HTP significantly cut down LID by about 50% without compromising L-DOPA's effectiveness at lower doses. However, using higher doses showed some reduction in L-DOPA's therapeutic effects. Despite these variations, 5-HTP proved beneficial and could be a promising treatment option for reducing dyskinesia in Parkinson's patients, highlighting the serotonin system's critical role in managing these symptoms.
7
We examined how 5-hydroxy-tryptophan (5-HTP) affects L-DOPA-induced dyskinesia (LID) in a mouse model of Parkinson's disease.
Using MitoPark mice treated with L-DOPA, we found that 5-HTP significantly reduced abnormal limb movements over time.
In contrast, while Citalopram also helped alleviate LID, it primarily affected different movement types.
Overall, both treatments showed promise but highlighted distinct pathways in managing motor symptoms related to Parkinson's.
Using MitoPark mice treated with L-DOPA, we found that 5-HTP significantly reduced abnormal limb movements over time.
In contrast, while Citalopram also helped alleviate LID, it primarily affected different movement types.
Overall, both treatments showed promise but highlighted distinct pathways in managing motor symptoms related to Parkinson's.
7
5-HTP shows potential sleep benefits
We explored the impact of 5-hydroxytryptophan (5-HTP) on REM sleep behavior disorder in patients with Parkinson's disease. In a small, randomized, double-blind trial with 18 participants, we compared daily doses of 5-HTP to a placebo over four weeks. The results suggested that 5-HTP can improve sleep quality and stability without increasing REM sleep disorder episodes. However, the overall benefits were marginal and further research with larger groups and longer durations is essential to confirm these findings.
7
We conducted a randomized, double-blind study to examine the effects of 5-Hydroxytryptophan (5-HTP) on motor complications caused by levodopa in 12 Parkinson's disease patients. Throughout the 16-week trial, involving a crossover design, we compared the effects of 5-HTP with a placebo.
While our results showed potential benefits in reducing levodopa-induced dyskinesias, they remain preliminary and warrant further investigation in larger studies. Overall, this suggests that 5-HTP might help alleviate some motor issues in Parkinson's patients, but more research is needed to confirm its effectiveness.
While our results showed potential benefits in reducing levodopa-induced dyskinesias, they remain preliminary and warrant further investigation in larger studies. Overall, this suggests that 5-HTP might help alleviate some motor issues in Parkinson's patients, but more research is needed to confirm its effectiveness.
7
We set out to explore if 5-hydroxytryptophan (5-HTP) could alleviate depression and apathy in Parkinson's disease (PD) patients. In a double-blind, placebo-controlled trial, 25 individuals received either 50 mg of 5-HTP or a placebo daily for four weeks.
Our findings suggest that while 5-HTP may benefit depressive symptoms, the overall impact on apathy appears limited. Larger studies over longer durations are needed to confirm these initial insights.
Our findings suggest that while 5-HTP may benefit depressive symptoms, the overall impact on apathy appears limited. Larger studies over longer durations are needed to confirm these initial insights.
User Reviews
USERS' SCORE
Good
Based on 14 Reviews
8
- All Reviews
- Positive Reviews
- Negative Reviews
9
Improved emotional health
8 people found this helpful
Following the intake of 5-HTP, symptoms of depression, apathy, and anxiety diminish; sleep becomes regular, and overall mood improves significantly. Notably, it alleviates symptoms of migraine and Parkinson's disease while enhancing concentration and overall productivity. A dosage of 50 to 300 mg per day is recommended.
9
Enhances serotonin regulation
5-HTP increases serotonin, crucial for mood regulation and addressing depression, anxiety, and sleep issues. Studies indicate it aids in reducing Parkinson's symptoms across multiple areas, making it an effective supplement for patients struggling with this condition.
9
Boosts mood and sleep
5-HTP enhances mood by raising serotonin levels, significantly reducing anxiety and alleviating symptoms associated with Parkinson's disease. It also positively affects sleep quality by promoting deeper, more restful sleep, which is crucial for overall emotional and physical health.
7.5
Alleviates Parkinson's symptoms
354 people found this helpful
SUPER !!!!!!!!!!!!! MY CHOICE 
TESTED PRESS “YES”, YOU ARE NOT HARD, AND IT IS PLEASANT TO KNOW ME THAT I HELPED YOU !!! Now Foods, 5-HTP, 100 mg, 60 capsules
PAYMENT ONLY THROUGH ME 5-HTP is an amino acid that effectively helps relieve anxiety, stress and insomnia. This natural amino acid increases serotonin, melatonin and niacin, improving mood and sleep quality. Most importantly, it alleviates symptoms of Parkinson's disease, increases pain threshold, and relieves appetite. This product is not an antidepressant, has no side effects, and improves overall well-being, making it highly recommended.
TESTED PRESS “YES”, YOU ARE NOT HARD, AND IT IS PLEASANT TO KNOW ME THAT I HELPED YOU !!! Now Foods, 5-HTP, 100 mg, 60 capsules PAYMENT ONLY THROUGH ME 5-HTP is an amino acid that effectively helps relieve anxiety, stress and insomnia. This natural amino acid increases serotonin, melatonin and niacin, improving mood and sleep quality. Most importantly, it alleviates symptoms of Parkinson's disease, increases pain threshold, and relieves appetite. This product is not an antidepressant, has no side effects, and improves overall well-being, making it highly recommended.9
Reduces Parkinson's intensity
5-HTP reduces headaches and alleviates symptoms of Parkinson's disease. It stimulates the release of beta-endorphins, increases pain threshold, regulates appetite, and aids in sleep. Its ability to naturally regulate serotonin levels distinguishes it from traditionally prescribed neurostimulants.
Frequently Asked Questions
9
Improved emotional health
8 people found this helpful
Following the intake of 5-HTP, symptoms of depression, apathy, and anxiety diminish; sleep becomes regular, and overall mood improves significantly. Notably, it alleviates symptoms of migraine and Parkinson's disease while enhancing concentration and overall productivity. A dosage of 50 to 300 mg per day is recommended.
9
Enhances serotonin regulation
5-HTP increases serotonin, crucial for mood regulation and addressing depression, anxiety, and sleep issues. Studies indicate it aids in reducing Parkinson's symptoms across multiple areas, making it an effective supplement for patients struggling with this condition.
7.5
Symptom relief
5-HTP is an amino acid that is increasingly recognised for its "antidepressant" properties. Depression often results from a deficiency of serotonin in the brain, known as the happiness hormone. Its deficiency can lead to depression, apathy, anxiety, sleep disturbances, and increased appetite. 5-HTP helps stabilise serotonin production while positively influencing mood and emotional state. Additionally, it aids melatonin production, crucial for sound sleep. Its effects include alleviation of depressive states and anxiety, improved sleep, mood, emotional balance, attention concentration, and efficiency. It also mitigates symptoms of migraine and parkinson, increases pain thresholds, alleviates PMS symptoms, and aids in discarding bad habits while normalising appetite. Start with 100 mg per day before gradually increasing.
9
Boosts mood and sleep
5-HTP enhances mood by raising serotonin levels, significantly reducing anxiety and alleviating symptoms associated with Parkinson's disease. It also positively affects sleep quality by promoting deeper, more restful sleep, which is crucial for overall emotional and physical health.
7.5
Mood enhancement
Excellent! This supplement effectively increases the pain threshold, reducing headaches and improving mood while alleviating anxiety. It can also help control appetite during intake. When treating parkinson, preparations with 5-HTP can ease symptoms, aiding individuals in overcoming addictions—such as smoking or alcoholism—without excessive stress.
7.5
Balanced emotions
5-HTP is a popular amino acid praised for its "antidepressant" properties. Depression often arises from serotonin depletion in the brain, leading to feelings of sadness and anxiety. 5-HTP helps restore serotonin levels, positively impacting mood and emotional balance, while also regulating melatonin for better sleep. Benefits include alleviation of depressive symptoms and anxiety, improved sleep, enhanced mood, increased efficiency, and relief from parkinson symptoms. Start with 100 mg daily and adjust as needed for optimal results.
7.5
Facilitates Parkinson's treatment
This supplement enhances mood and reduces anxiety while controlling appetite. It aids in treating Parkinson's disease by alleviating symptoms during treatment with 5-HTP. Furthermore, it supports those overcoming addictions by easing withdrawal symptoms, stabilising blood pressure, and improving blood circulation – benefiting the cardiovascular system significantly.
7
We examined how 5-hydroxy-tryptophan (5-HTP) affects L-DOPA-induced dyskinesia (LID) in a mouse model of Parkinson's disease.
Using MitoPark mice treated with L-DOPA, we found that 5-HTP significantly reduced abnormal limb movements over time.
In contrast, while Citalopram also helped alleviate LID, it primarily affected different movement types.
Overall, both treatments showed promise but highlighted distinct pathways in managing motor symptoms related to Parkinson's.
Using MitoPark mice treated with L-DOPA, we found that 5-HTP significantly reduced abnormal limb movements over time.
In contrast, while Citalopram also helped alleviate LID, it primarily affected different movement types.
Overall, both treatments showed promise but highlighted distinct pathways in managing motor symptoms related to Parkinson's.
8
We evaluated how 5-hydroxy-tryptophan (5-HTP) might help reduce L-DOPA-induced dyskinesia (LID) in a Parkinson’s disease rat model. Through controlled studies, we found that 5-HTP significantly cut down LID by about 50% without compromising L-DOPA's effectiveness at lower doses. However, using higher doses showed some reduction in L-DOPA's therapeutic effects. Despite these variations, 5-HTP proved beneficial and could be a promising treatment option for reducing dyskinesia in Parkinson's patients, highlighting the serotonin system's critical role in managing these symptoms.
7
We conducted a randomized, double-blind study to examine the effects of 5-Hydroxytryptophan (5-HTP) on motor complications caused by levodopa in 12 Parkinson's disease patients. Throughout the 16-week trial, involving a crossover design, we compared the effects of 5-HTP with a placebo.
While our results showed potential benefits in reducing levodopa-induced dyskinesias, they remain preliminary and warrant further investigation in larger studies. Overall, this suggests that 5-HTP might help alleviate some motor issues in Parkinson's patients, but more research is needed to confirm its effectiveness.
While our results showed potential benefits in reducing levodopa-induced dyskinesias, they remain preliminary and warrant further investigation in larger studies. Overall, this suggests that 5-HTP might help alleviate some motor issues in Parkinson's patients, but more research is needed to confirm its effectiveness.
7
We set out to explore if 5-hydroxytryptophan (5-HTP) could alleviate depression and apathy in Parkinson's disease (PD) patients. In a double-blind, placebo-controlled trial, 25 individuals received either 50 mg of 5-HTP or a placebo daily for four weeks.
Our findings suggest that while 5-HTP may benefit depressive symptoms, the overall impact on apathy appears limited. Larger studies over longer durations are needed to confirm these initial insights.
Our findings suggest that while 5-HTP may benefit depressive symptoms, the overall impact on apathy appears limited. Larger studies over longer durations are needed to confirm these initial insights.
7
5-HTP shows potential sleep benefits
We explored the impact of 5-hydroxytryptophan (5-HTP) on REM sleep behavior disorder in patients with Parkinson's disease. In a small, randomized, double-blind trial with 18 participants, we compared daily doses of 5-HTP to a placebo over four weeks. The results suggested that 5-HTP can improve sleep quality and stability without increasing REM sleep disorder episodes. However, the overall benefits were marginal and further research with larger groups and longer durations is essential to confirm these findings.
References
- Chen YH, Kuo TT, Wang V, Cheng PW, Huang EY, et al. Serotonergic Regulation of Synaptic Dopamine Levels Mitigates L-DOPA-Induced Dyskinesia in a Mouse Model of Parkinson's Disease. J Parkinsons Dis. 2024;14:941. 10.3233/JPD-240080
- Meloni M, Figorilli M, Carta M, Tamburrino L, Cannas A, et al. Preliminary finding of a randomized, double-blind, placebo-controlled, crossover study to evaluate the safety and efficacy of 5-hydroxytryptophan on REM sleep behavior disorder in Parkinson's disease. Sleep Breath. 2022;26:1023. 10.1007/s11325-021-02417-w
- Meloni M, Puligheddu M, Sanna F, Cannas A, Farris R, et al. Efficacy and safety of 5-Hydroxytryptophan on levodopa-induced motor complications in Parkinson's disease: A preliminary finding. J Neurol Sci. 2020;415:116869. 10.1016/j.jns.2020.116869
- Meloni M, Puligheddu M, Carta M, Cannas A, Figorilli M, et al. Efficacy and safety of 5-hydroxytryptophan on depression and apathy in Parkinson's disease: a preliminary finding. Eur J Neurol. 2020;27:779. 10.1111/ene.14179
- Tronci E, Fidalgo C, Stancampiano R, Carta M. Effect of selective and non-selective serotonin receptor activation on L-DOPA-induced therapeutic efficacy and dyskinesia in parkinsonian rats. Behav Brain Res. 2015;292:300. 10.1016/j.bbr.2015.06.034
- Tronci E, Lisci C, Stancampiano R, Fidalgo C, Collu M, et al. 5-Hydroxy-tryptophan for the treatment of L-DOPA-induced dyskinesia in the rat Parkinson's disease model. Neurobiol Dis. 2013;60:108. 10.1016/j.nbd.2013.08.014
- Aubin N, Barneoud P, Carter C, Caille D, Sontag N, et al. SL25.1131 [3(S),3a(S)-3-methoxymethyl-7-[4,4,4-trifluorobutoxy]-3,3a,4,5-tetrahydro-1,3-oxazolo[3,4-a]quinolin-1-one], a new, reversible, and mixed inhibitor of monoamine oxidase-A and monoamine oxidase-B: biochemical and behavioral profile. J Pharmacol Exp Ther. 2004;310:1171.
- Mayeux R, Stern Y, Sano M, Williams JB, Cote LJ. The relationship of serotonin to depression in Parkinson's disease. Mov Disord. 1988;3:237.
